Ruengies, OT - Concerning Cortex, here's a post from Dew's Biotech Values board which I'll repost here for anyone curious about Cortex -
>>> Dew, Of course the big driver for Cortex's share price in the near term is the FDA dosing decision, which is my primary interest at the moment. Once that is past and we've doubled our money :o), then we can fully evaluate the various other factors for the company, like the prospects for lucrative partnering deals (CX-717/ADHD, Neurodegenerative/high impacts, CX-701, CX-1501, inlicensed programs, etc).
With the lifting of the dosing restrictions, pharma interest in CX-717/ADHD should be very strong, based on the stellar Phase 2a results, and on CX-717's total lack of systemic/cardio side effects. The reunified global Neurodegenerative Ampakine rights, and the high impact platform, will make for another excellent BP deal. And as we know, with partner Organon getting bought by Schering recently, the global Schizo/Depression rights may now be up for grabs also. A BP with an interest in AMPA upmodulation, like Lilly or Glaxo, could now realistically go after control of all the rights, indications, and territories, and while they're at it buy Cortex outright and take command of Cortex's broad use patent estate (cognition/memory, neurotrophin upregulation, schizophrenia, etc) as well as Cortex's huge library of high and low impact compounds.
AMPA upmodulation is arguably the most promising new broad neuro platform, and it's virtually owned by Cortex, with a lock on the IP via their broad use patents, and with the only compound family to have success in human trials. And as you indicated, the high impact platform in particular has truly massive potential - nothing short of treating virtually every neurodegenerative disease state via the upregulation of BDNF/brain neurotrophins. All this and a market cap of only $100 mil :o) <<<
Market Data 
Markets 
AI
